Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $5.2 million, with staking revenue of $5.1 million, marking a significant increase from the prior year [20] - Total revenue for the full year 2025 was $6 million, compared to $0.5 million for the full year 2024 [20] - The company reported a net income of $325.6 million for Q4 2025, or earnings of $4.25 per share, compared to a net loss of $3.9 million in the prior year period [23] - For the full year 2025, the net loss was $40.9 million, or a loss of $1.85 per share, compared to a net loss of $11.7 million in 2024 [24] Business Line Data and Key Metrics Changes - The company staked substantially all of its SOL holdings, achieving an average net staking yield of 6.8% for Q4 2025, outperforming the system-wide average of 6.2% [13] - Year to date in 2026, the staking yield increased to 7.0% APY compared to the system-wide average of 6.0% [14] - The company executed over $3 million in share repurchases year to date under its buyback program, funded primarily by the sale of Solana at prices that were accretive to NAV per share [17] Market Data and Key Metrics Changes - The company highlighted the Asia-Pacific region as a significant market, representing the majority of the world's crypto users and a substantial share of global cross-border payments and trading activities [10] - The Pacific Backbone initiative aims to invest in a new low-latency cluster across the Asia-Pacific region to support ecosystem development and diversify revenue streams [10] Company Strategy and Development Direction - The company is focused on creating long-term shareholder value by growing SOL per share and contributing to the growth of the Solana ecosystem through capital markets, asset management, and marketing partnerships [5] - The company plans to establish strategic partnerships with major financial institutions to support payment and tokenization initiatives [9] - The collaboration with Anchorage Digital and Kamino aims to enable borrowing against natively staked SOL, enhancing yield generation opportunities [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the evolving digital asset treasury market, emphasizing the importance of disciplined capital management and strategic partnerships [12] - The management team acknowledged the need for regulatory clarity in the DeFi space to attract more institutional participation [56] - The company is optimistic about the growth potential of the Solana ecosystem, particularly in the tokenization of real-world assets [63] Other Important Information - As of December 31, 2025, the company held 2.36 million SOL tokens and $7 million in cash and stablecoins, with total assets of $303 million [25] - The company reported a significant unrealized loss of $178.3 million on digital intangible assets, impacting operating expenses [22] Q&A Session Summary Question: What incremental capital raising structures are being evaluated? - The company is exploring various capital markets opportunities, including convertible debt and structured equity products, while focusing on accretive options for shareholders [29][30] Question: What does "highly selective" mean in practice for strategic capital markets transactions? - Management emphasized the importance of raising capital at the right level to ensure shareholder accretion and bringing in high-quality strategic investors [34] Question: Is the Anchorage collaboration active today? - The Anchorage partnership is still being developed, with expectations for deployment in a risk-managed way [54]

Financial Data and Key Metrics Changes - For Q4 2025, general and administrative expenses were approximately $1.5 million, a slight decrease from $1.6 million in Q4 2024. R&D expenses were approximately $2.7 million, down from $4.3 million in the same period last year. The net loss for Q4 2025 was approximately $4.1 million, or $0.36 per share, compared to a net loss of $5.9 million, or $0.54 per share in Q4 2024 [32][33] - For the full year 2025, R&D expenses totaled approximately $11.5 million, down from $16.1 million in 2024, primarily due to a reduction in research studies and materials. General and administrative expenses increased slightly to approximately $6.5 million from $6.1 million in 2024. The net loss for 2025 was approximately $17.1 million, or $1.57 per share, compared to $20.8 million, or $1.93 per share in 2024 [33][35] Business Line Data and Key Metrics Changes - The company achieved clinical validation across multiple programs, including LP-300 and LP-184, with significant milestones in their clinical trials. The LP-300 program specifically targets lung cancer in never smokers, representing a substantial market opportunity of over $4 billion annually [3][7] - The LP-184 phase I results showed a 48% clinical benefit rate in heavily pretreated advanced cancer patients, validating the synthetic lethality hypothesis and indicating potential for further development in precision oncology trials [10][11] Market Data and Key Metrics Changes - The estimated annual market potential for the company's AI-driven clinical pipeline exceeds $15 billion and approaches $20 billion, with a focus on solid tumors, blood cancers, and pediatric oncology [4] - The company is actively exploring collaboration opportunities globally to maximize the commercial potential of LP-300, with ongoing discussions with regional and global pharma companies [10] Company Strategy and Development Direction - The company is positioning itself to advance clinical programs and expand the RADR platform's commercial reach globally through a new AI Center of Excellence in India, aiming to strengthen its balance sheet and enhance revenue potential [4][24] - The strategic focus includes leveraging AI and machine learning to transform drug development processes, with a vision to create a new paradigm in precision oncology [2][40] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of AI technologies in drug discovery and the potential for significant returns as the industry matures towards an AI-centric approach. They highlighted the need for rapid advancements in drug development to meet the urgent needs of cancer patients [2][40] - The company plans to pursue additional funding and partnerships to support ongoing clinical trials and operational advancements, indicating a proactive approach to financial sustainability [39][41] Other Important Information - The company cleared an IND for a pediatric CNS cancer trial through Starlight Therapeutics, marking a significant regulatory milestone and positioning the company for further clinical development across various patient demographics [16][22] - The RADR AI platform integrates extensive oncology-focused data and machine learning algorithms, with plans for commercialization and expansion into other therapeutic areas beyond cancer [24][31] Q&A Session Summary Question: What are the upcoming milestones for the LP-300 program? - The company has a Type C meeting scheduled with the FDA to discuss protocol amendments for the LP-300 trial, focusing on specific patient populations and treatment cycles [38] Question: How is the company addressing funding needs? - The company is actively evaluating and pursuing potential funding alternatives to support its anticipated operating expenses and capital requirements [36]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $7 million, a decrease of 13% from $8.1 million in Q4 2024 [12] - Full year revenue for 2025 was $30.6 million, down from $34.6 million in 2024 [12] - Net income after tax for Q4 2025 was $1.6 million or $0.11 per diluted share, compared to $2.2 million or $0.16 per diluted share in Q4 2024 [16] - Full year net income was $6.3 million or $0.45 per diluted share, up from $3.7 million or $0.26 per diluted share in 2024 [17] - Adjusted EBITDA for Q4 2025 was $3.4 million, down from $3.8 million in Q4 2024 [18] Business Line Data and Key Metrics Changes - Franchise royalties for Q4 2025 were $6.6 million, down from $7.6 million in Q4 2024 [12] - For the full year, franchise royalties were $29 million compared to $32.7 million in 2024 [13] - Service revenue in Q4 2025 was $392,000, compared to $428,000 in Q4 2024 [13] - System-wide sales in Q4 2025 were $122.3 million, a decrease of 9.3% from $134.8 million in Q4 2024 [13] Market Data and Key Metrics Changes - A survey of over 400 offices indicated that 68% reported steady time to fill for open roles in 2025, while 35% saw increases [9] - 61% of recruiters expect time to fill to remain stable in 2026, with 15% expecting improvement as candidate supply normalizes [9] Company Strategy and Development Direction - The company announced a strategic decision to divest the permanent placement piece of MRINetwork into a new entity, transitioning majority ownership to a leadership group of current and former franchise owners [5] - HireQuest remains committed to MRINetwork, retaining partial ownership and supporting the brand with essential infrastructure [6] - A share repurchase program was approved, allowing the company to repurchase up to $20 million of its outstanding shares [7] Management Comments on Operating Environment and Future Outlook - The macro environment has created challenges for the staffing industry, but the company remains solidly profitable [4] - The labor market is expected to stabilize around new priorities, including flexibility and skilled work that cannot be automated by AI [9] - Key trends for 2026 include AI and automation, reshoring, and economic shifts [10] Other Important Information - Total assets as of December 31, 2025, were $88.2 million, down from $94 million at the end of 2024 [18] - The company ended 2025 with $33 million in working capital, an increase from $25.1 million at the end of 2024 [19] - The company has paid a regular quarterly dividend since Q3 2020, with the most recent dividend being $0.06 per common share [19] Q&A Session Summary Question: Impact of stabilization on divisions - Management noted that stabilization in the market has not been more pronounced in any particular division but is apparent across the board [23] Question: MRI transaction revenue and expense impact - Management indicated that about 35%-40% of the retained revenue from MRI comes from contract staffing, with the permanent placement division being breakeven [25][26] Question: Update on acquisition pipeline - Management stated that there has been a dry spell in finding suitable acquisitions, emphasizing that they will not chase deals just for the sake of it [28][29]

Financial Data and Key Metrics Changes - The net loss attributable to common stockholders for the year ended December 31, 2025, was approximately $45.9 million, compared to approximately $42.1 million for 2024, indicating an increase in losses [23] - Research and development expenses totaled approximately $20.7 million for the year ended December 31, 2025, down from approximately $33.2 million for 2024, primarily due to lower expenses related to the Alzheimer's trial [23] - General and administrative expenses were approximately $10.3 million for the year ended December 31, 2025, compared to approximately $9.5 million for 2024 [23] Business Line Data and Key Metrics Changes - CORDStrom is positioned as the most advanced program and a major value driver for the company, with significant progress in the RDEB program, including clinically meaningful wound healing and improvements in quality of life [5][6] - The XPro program for Alzheimer's disease is in a strong position, having completed the MINDFuL trial and aligned with the FDA on the development path, preparing for a phase III trial [7][8] Market Data and Key Metrics Changes - The company has successfully completed its phase II trial in metastatic castration-resistant prostate cancer ahead of schedule and under budget, meeting its primary endpoint and two of its three secondary endpoints [8] Company Strategy and Development Direction - The company aims to execute against important regulatory, clinical, and strategic milestones across its portfolio, with a focus on advancing CORDStrom towards registration and preparing for the phase III trial of XPro [5][9] - CORDStrom is not only a single asset opportunity but also a platform with broader potential for development in additional inflammatory and degenerative conditions [6] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of capital efficiency and maintaining a lean, execution-oriented culture to maximize shareholder value while minimizing unnecessary burn [21] - The company believes that 2026 will be a pivotal year, with multiple meaningful opportunities to create value as it advances CORDStrom towards approval and clarifies the next steps for XPro [26] Other Important Information - The company sold three million shares of common stock for net proceeds of approximately $17.4 million and approximately 1.3 million shares for net proceeds of approximately $10.1 million during 2025 [24] - As of December 31, 2025, the company had cash and cash equivalents of approximately $24.8 million, which is expected to fund operations through Q1 2027 [24] Q&A Session Summary Question: Anticipated differences between MAA and FDA submission - Mark Lowdell explained that the FDA requires U.K. donor materials to be screened for infectious disease markers in U.S. labs, necessitating the creation of new master seed stock for U.S. submission [32][33] Question: Interest in potential pharma partners for XPro - David Moss mentioned ongoing discussions with various groups and the intention to find a partner to support business development, highlighting the program's attractiveness due to its potential in a large market [46][48]

Financial Data and Key Metrics Changes - Net premiums earned for Q4 2025 decreased to $555,000 from $595,000 in Q4 2024, attributed to lower average rates on reinsurance contracts [6][10] - Total revenue for Q4 2025 was $576,000, up from $422,000 in the prior year [8][11] - Net income for Q4 2025 was $120,000 or $0.02 per share, compared to a net loss of $460,000 or $0.05 per share in Q4 2024 [13] - For the fiscal year 2025, total revenues reached $2.58 million, compared to $546,000 in 2024 [11][12] - Net loss for the year 2025 was $2.08 million or $0.20 per share, an improvement from a net loss of $2.73 million or $0.45 per share in 2024 [14][15] Business Line Data and Key Metrics Changes - The loss ratio increased to 80.9% for Q4 2025 and 119.9% for the fiscal year 2025, primarily due to losses from Hurricane Milton [16][18] - The acquisition cost ratio remained stable at 11% for both the quarter and year ended December 31, 2025 [17] - The expense ratio increased to 106.7% for Q4 2025 and 144.2% for the fiscal year 2025, reflecting higher operational costs [17][18] Market Data and Key Metrics Changes - The investment portfolio decreased to $0 at December 31, 2025, from $115,000 the previous year, due to the sale of equity securities [19] - Cash and cash equivalents increased to approximately $7 million from $5.89 million as of December 31, 2024, driven by new collateral deposits [19][20] Company Strategy and Development Direction - The company focuses on disciplined reinsurance business with a strategy centered on low frequency, high severity risks [4][5] - SurancePlus aims to expand reinsurance on-chain, broadening access to a historically limited asset class [5] - The company is exploring opportunities in tokenizing data center revenue streams, particularly related to AI growth [21][25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the 2026/2027 contract cycle, targeting returns of 20% and 42% for their offerings [21] - Industry reports suggest favorable conditions due to El Niño, presenting potential opportunities [21] - The company believes its current market valuation does not reflect its balance sheet strength and ongoing opportunities [21] Other Important Information - The company has made significant progress in expanding its platform through strategic relationships, including entry into the Solana ecosystem [21] - The Balanced-Yield Token is tracking 25% ahead of its 20% target, while the High-Yield Token is on track with its 42% target [20] Q&A Session Summary Question: Can you expand on the tokenization of artificial intelligence infrastructure? - Management confirmed they are evaluating strategic relationships for data center revenue streams, which could enhance shareholder value [24][25] Question: Is the company in a good position regarding cash balances? - Management stated they have about $6.9 million in cash and restricted cash, positioning them well for future opportunities [27]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $7 million, a decrease of 13% from $8.1 million in Q4 2024 [12] - For the full year 2025, total revenue was $30.6 million compared to $34.6 million in 2024 [12] - Net income after tax for Q4 2025 was $1.6 million or $0.11 per diluted share, down from $2.2 million or $0.16 per diluted share in Q4 2024 [16] - Full year net income was $6.3 million or $0.45 per diluted share, compared to $3.7 million or $0.26 per diluted share in 2024 [17] - Adjusted EBITDA for Q4 2025 was $3.4 million, down from $3.8 million in Q4 2024 [18] Business Line Data and Key Metrics Changes - Franchise royalties for Q4 2025 were $6.6 million, down from $7.6 million in Q4 2024 [12] - For the full year 2025, franchise royalties were $29 million compared to $32.7 million in 2024 [13] - Service revenue in Q4 2025 was $392 thousand, compared to $428 thousand in Q4 2024 [13] Market Data and Key Metrics Changes - System-wide sales in Q4 2025 were $122.3 million, a decrease of 9.3% from $134.8 million in Q4 2024 [13] - For the full year, system-wide sales were $500.2 million, down 11.3% from $563.6 million in 2024 [13] - 68% of surveyed offices reported steady time to fill for open roles in 2025, indicating market stability [9] Company Strategy and Development Direction - The company divested the permanent placement piece of MRI Network to a new entity, transitioning majority ownership to a leadership group of franchise owners [5] - HireQuest remains committed to MRI Network, retaining partial ownership and supporting the brand with essential infrastructure [6] - A share repurchase program was approved, allowing the company to repurchase up to $20 million of its outstanding shares [7] Management's Comments on Operating Environment and Future Outlook - The macro environment has posed challenges for the staffing industry, but the company remains profitable and executed well in 2025 [4] - The labor market is expected to stabilize around new priorities, including flexibility and skilled labor that cannot be automated [9] - Key trends for 2026 include AI and automation, reshoring, and economic shifts [10] Other Important Information - Total assets as of December 31, 2025, were $88.2 million, down from $94 million at the end of 2024 [18] - The company ended 2025 with $33 million in working capital, an increase from $25.1 million at the end of 2024 [19] - A regular quarterly dividend of $0.06 per common share was paid on March 16, 2025 [19] Q&A Session Summary Question: Impact of stabilization on divisions - Management noted that stabilization in the market has not been more pronounced in any particular division but is evident across the board [24] Question: Quantification of MRI transaction impact - The executive search portion of MRI contributed about $65 million in system-wide sales and just under $2 million for royalties in 2025, with minimal impact on profitability expected [27] Question: Update on acquisition pipeline - Management indicated a lack of recent acquisition activity, citing a dry spell in finding suitable deals, but remains open to opportunities [30]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported a net loss of $35.7 million, an increase from a $24.7 million loss in Q4 2024, primarily due to a $6.8 million increase in impairment expense and a $3.4 million increase in foreign exchange loss [22][23][25] - The full year 2025 net loss was $48.4 million, compared to a shorter six-month fiscal stub period in 2024 [30][31] - Cash and working capital positions improved significantly to $152.3 million and $147.6 million, respectively, compared to $31.2 million and $27.5 million in the prior year [32] Business Line Data and Key Metrics Changes - The SWA project is expected to have a production capacity of 22,500 tons per year of battery-quality lithium carbonate in its initial phase [5] - The maiden resource estimate for the Franklin Project in East Texas indicates some of the highest reported lithium in brine grades in North America, supporting future scalable production [6][7] Market Data and Key Metrics Changes - The company received indications of interest for over $1 billion in project financing for the SWA project from major export credit agencies and commercial banks, exceeding the targeted debt amount [9] - The company aims to secure approximately 80% of its planned lithium carbonate production under long-term offtake contracts, with the first agreement with Trafigura for 8,000 tons representing over 40% of the initial phase [17] Company Strategy and Development Direction - The company is focused on advancing the SWA project and expanding its operations in East Texas, with plans to release a preliminary feasibility study for the Franklin project within the next 12 months [20][21] - The company is prioritizing projects with the best grades and potential for larger scale, particularly in East Texas, while refocusing efforts away from the LANXESS project [23][72] Management's Comments on Operating Environment and Future Outlook - Management noted that the lithium pricing environment has improved, leading to increased interest from potential counterparties for offtake agreements [44][46] - The company is confident in its ability to reach a satisfactory outcome in customer offtake negotiations, which are critical for the final investment decision (FID) [19][60] Other Important Information - The company closed a $130 million upsized public offering in October, which has strengthened its financial position [8] - The project financing for the SWA project is expected to be a combination of senior secured project debt, a $225 million grant from the DOE, and equity contributions from Standard Lithium and Equinor [36][38] Q&A Session Summary Question: Changes in offtake discussions over the last six to twelve months - Management indicated that the market has evolved positively, with more counterparties interested in discussions due to improved lithium pricing [44][46] Question: Expectation of another offtake agreement before financing concludes - Management confirmed the plan to have over 80% of volumes contracted prior to FID, with announcements expected in the coming quarter [47] Question: Clauses or caveats project debt lenders are looking for in offtake contracts - Management stated that the 80% target is an internal standard, and the percentage contracted will depend on the terms across various agreements [52] Question: Construction period and CapEx timeline - Management guided towards commercial production in 2029, with ongoing refinements to the construction schedule [55] Question: Gating items to FID - Management identified offtake agreements as the hardest to predict in terms of timing, while other processes are progressing well [58] Question: Inflationary pressures for CapEx items - Management noted that vendor pricing is currently stable, with allowances made for potential price growth in final contracts [95]

Financial Data and Key Metrics Changes - Net premiums earned for the three months ended December 31, 2025, decreased to $555,000 from $595,000 for the same period in 2024, attributed to lower weighted average rates on reinsurance contracts [7][10] - Total revenue for the three months ended December 31, 2025, amounted to $576,000, compared to $422,000 in the prior year [8][11] - Net income for the quarter ending December 31, 2025, was $120,000 or $0.02 per share, compared to a net loss of $460,000 or $0.05 per share for the same quarter in 2024 [13] - For the fiscal year ended December 31, 2025, total revenues were $2.58 million, compared to $546,000 in the prior year [11][14] Business Line Data and Key Metrics Changes - The loss ratio increased to 80.9% for the three-month period ended December 31, 2025, and 119.9% for the fiscal year, primarily due to losses from Hurricane Milton [15][17] - The acquisition cost ratio remained consistent at 11% for both the quarter and year ended December 31, 2025 [16] - The expense ratio increased to 106.7% for the three months and 144.2% for the fiscal year ended December 31, 2025, due to increased professional costs and losses incurred [16][17] Market Data and Key Metrics Changes - The investment portfolio decreased to $0 at December 31, 2025, from $115,000 the prior year-end, due to the sale of equity securities [18] - Cash and cash equivalents increased by $1.08 million to approximately $7 million from $5.89 million as of December 31, 2024, primarily due to new collateral deposits [18][19] Company Strategy and Development Direction - The company focuses on disciplined reinsurance business with a strategy centered on low frequency, high severity risk, emphasizing data-driven underwriting and full collateralization [4][5] - SurancePlus aims to expand reinsurance on-chain, broadening access to an asset class traditionally limited to institutional partnerships [5] - The company is exploring opportunities to extend its model into high-quality, cash-generating assets, including the tokenization of data center revenue streams related to AI growth [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the favorable risk environment due to El Niño conditions and the potential opportunities it presents [20] - The company believes its current market valuation does not fully reflect its balance sheet strength and ongoing opportunities to drive shareholder value [21] Other Important Information - The company recorded underwriting losses due to adverse developments from Hurricane Milton, impacting both quarterly and annual results [12][13] - The Balanced-Yield Token is tracking 25% ahead of its 20% target, while the High-Yield Token is tracking its 42% target, reflecting the effectiveness of the company's disciplined underwriting approach [19] Q&A Session Summary Question: Can you expand on the tokenization of artificial intelligence infrastructure? - Management indicated that they are evaluating strategic relationships for data center revenue streams, which could significantly enhance shareholder value [24] Question: Do you have sufficient cash to move forward with your plans? - Management confirmed having approximately $6.9 million in cash and restricted cash, positioning the company well for future opportunities [26]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased by 1% year-over-year to $4.3 million, driven by SaaS growth which offset declines in other revenue lines [8] - For the full year 2025, total revenue decreased by 8% to $16.6 million compared to $18 million in 2024, primarily due to variability in services activity [11] - Adjusted EBITDA for Q4 was $261 thousand, down from $531 thousand in the same period last year, reflecting a shift in revenue mix and increased investments [10] Business Line Data and Key Metrics Changes - SaaS revenue, including hosting, increased by 8.4% to $1.6 million in Q4 2025 from $1.5 million in Q4 2024 [8] - Professional services revenue decreased by 1.8% to approximately $2.2 million in Q4, representing 51% of total revenue, down from 52% the previous year [9] - For the full year, SaaS revenue grew by 11.1%, while professional services revenue decreased by 18.7% to $8.1 million [11] Market Data and Key Metrics Changes - SaaS growth was noted despite economic headwinds in vertical markets such as construction, home building, and K-12 education [11] - The company experienced a favorable revenue mix shift, contributing to an increase in consolidated gross margin to 66% for the full year, up from 63% [11] Company Strategy and Development Direction - The company is focused on improving execution, sharpening its go-to-market approach, and accelerating SaaS revenue while enhancing consistency in its document management business [4][15] - Management emphasized the importance of foundational assets, a growing SaaS business, and differentiated technology as key components for long-term value creation [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of SaaS revenues for fiscal year 2026, contingent on current plans and assumptions [14] - The CEO highlighted the need for improved execution and the potential for consistent performance moving forward [15] Other Important Information - Operating expenses increased by 11.2% to $3.1 million in Q4 2025, driven by investments in sales and marketing and general administrative expenses [10] - The company reported a net loss of $1.873 million for the full year 2025, compared to a net loss of $546,000 in 2024 [12] Q&A Session Summary - The Q&A session was conducted but no specific questions or answers were documented in the provided content [17]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $5.2 million, with staking revenue of $5.1 million, marking a significant increase from the prior year [19] - Total revenue for the full year 2025 was $6 million, compared to $0.5 million for the full year 2024 [19] - The company reported a net income of $325.6 million for Q4 2025, or earnings of $4.25 per share, compared to a net loss of $3.9 million in the prior year period [22] - For the full year 2025, the net loss was $40.9 million, or a loss of $1.85 per share, compared to a net loss of $11.7 million in 2024 [23][24] Business Line Data and Key Metrics Changes - The company staked substantially all of its SOL holdings, achieving an average net staking yield of 6.8% for Q4 2025, outperforming the system-wide average of 6.2% [13] - Year-to-date in 2026, the staking yield increased to 7.0% APY compared to the system-wide average of 6.0% [13] Market Data and Key Metrics Changes - The company is focusing on expanding its presence in the Asia-Pacific region, which represents a significant portion of global crypto users and cross-border payments [10] - The Pacific Backbone initiative aims to invest in a new low-latency cluster across Asia-Pacific, enhancing staking and validation capabilities [10] Company Strategy and Development Direction - The company is transitioning from a passive holding structure to a multifaceted platform with distinct value-adding activities, including capital markets, asset management, and marketing partnerships [5] - A strategic partnership with Anchorage Digital and Kamino was announced, enabling borrowing against natively staked SOL, which is expected to enhance yield generation [9] - The company aims to optimize capital formation through various structures, including convertible debt and strategic M&A [16] Management's Comments on Operating Environment and Future Outlook - Management believes the digital asset treasury market is entering a consolidation phase, with stronger operators differentiating themselves from others [12] - The company is optimistic about the growth of the Solana ecosystem and its positioning in the tokenization of real-world assets [61][62] - Management emphasized the importance of regulatory clarity for institutional participation in DeFi, which could enhance on-chain yield opportunities [55] Other Important Information - The company held 2.36 million SOL tokens and $7 million in cash and stablecoins as of December 31, 2025 [17] - Total assets were reported at $303 million, with total shareholders' equity at $300.9 million at year-end [24] Q&A Session Summary Question: What incremental capital-raising structures are being evaluated? - The company is exploring various capital markets opportunities, including convertible debt and structured equity products, while focusing on accretive actions for shareholders [26][29] Question: What does "highly selective" mean in practice for strategic capital markets transactions? - Management clarified that "highly selective" refers to raising capital at levels that are accretive to shareholders and bringing in high-quality strategic investors [31][34] Question: Is the Anchorage collaboration active today? - The Anchorage partnership is still being developed, with expectations for deployment in a risk-managed way soon [52][53]